Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yosuke Takamiya, Keisuke Okamura, Kazuyuki Shirai, Tetsu Okuda, Kunihisa Kobayashi & Hidenori Urata. (2020) Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T). Clinical and Experimental Hypertension 42:3, pages 197-204.
Read now
Read now
Mahmoud Barbarawi, Ahmed Aburahma, Yazan Zayed, Mohammed Osman, Laith Rashdan, Bakr Swaid & Ghassan Bachuwa. (2018) Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials. Journal of Community Hospital Internal Medicine Perspectives 8:6, pages 349-356.
Read now
Read now
Articles from other publishers (16)
Silviu Stanciu, Emilia Rusu, Daniela Miricescu, Ana Cristina Radu, Bianca Axinia, Ana Maria Vrabie, Ruxandra Ionescu, Mariana Jinga & Carmen Adella Sirbu. (2023) Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. Metabolites 13:1, pages 87.
Crossref
Crossref
Asima Khan, Izhan A. Khan, Hussain Abidi & Mansoor Ahmed. (2022) Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population. Frontiers in Endocrinology 13.
Crossref
Crossref
Fen Cao, Kun Wu, Yong-Zhi Zhu & Zhong-Wu Bao. (2021) Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging. Frontiers in Endocrinology 12.
Crossref
Crossref
Charalampos I. Liakos, Dimitrios P. Papadopoulos, Elias A. Sanidas, Maria I. Markou, Erifili E. Hatziagelaki, Charalampos A. Grassos, Maria L. Velliou & John D. Barbetseas. (2020) Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors). American Journal of Cardiovascular Drugs 21:2, pages 123-137.
Crossref
Crossref
Marina V. Shestakova, Ekaterina A. Shestakova & Vera A. Kachko. (2020) Specific features of the use of alogliptin in various groups of patients with type 2 diabetes mellitus: additional results of the ENTIRE study. Problems of Endocrinology 66:2, pages 49-60.
Crossref
Crossref
Valentina K. Bayrasheva, Ivan Y. Pchelin, Vladimir A. Dobronravov, Alina Yu. Babenko, Svetlana G. Chefu, Ivan S. Shatalov, Volha N. Vasilkova, Natalia V. Hudiakova, Alexandra N. Ivanova, Pavel A. Andoskin & Elena N. Grineva. (2020) Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes: open-label randomized prospective study. Archives of Endocrinology and Metabolism.
Crossref
Crossref
Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska & Bartosz Malinowski. (2020) Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis. International Journal of Molecular Sciences 21:7, pages 2275.
Crossref
Crossref
Peng GaoLi LiXiao WeiMiao WangYangning HongHao WuYanjia ShenTianyi MaXing WeiQin ZhangXia FangLijuan WangZhencheng YanGuan-Hua DuHongting ZhengGangyi YangDaoyan LiuZhiming Zhu. (2020) Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction. Hypertension 75:1, pages 150-162.
Crossref
Crossref
Julie R. Lundgren, Kristine Færch, Daniel R. Witte, Anna E. Jonsson, Oluf Pedersen, Torben Hansen, Torsten Lauritzen, Jens J. Holst, Dorte Vistisen, Marit E. Jørgensen, Signe S. Torekov & Nanna B. Johansen. (2019) Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Maryam Rameshrad, Bibi Marjan Razavi, Gordon A. A. Ferns & Hossein Hosseinzadeh. (2019) Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. DARU Journal of Pharmaceutical Sciences 27:1, pages 341-360.
Crossref
Crossref
Jianqiang Zhang, Qiuyue Chen, Jixin Zhong, Chaohong Liu, Bing Zheng & Quan Gong. (2019) DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs. Frontiers in Immunology 10.
Crossref
Crossref
Jianping Bi, Wusheng Cai, Teng Ma, Aiwei Deng, Ping Ma, Ye Han, Chunbiao Lou & Leilei Wu. (2019) Protective effect of vildagliptin on TNF‐α‐induced chondrocyte senescence. IUBMB Life.
Crossref
Crossref
Luciana Neves Cosenso-Martin, Luiz Tadeu Giollo-Júnior, Letícia Aparecida Barufi Fernandes, Cláudia Bernardi Cesarino, Marcelo Arruda Nakazone, Maurício de Nassau Machado, Juan Carlos Yugar-Toledo & José Fernando Vilela-Martin. (2018) Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial. Acta Diabetologica 55:12, pages 1237-1245.
Crossref
Crossref
Natsu Otowa-Suematsu, Kazuhiko Sakaguchi, Tomoaki Nakamura, Kenta Hara, Minoru Kishi, Naoko Hashimoto, Kazuki Yokota, Hiroshi Yoshino, Yasuo Kuroki, Tomoko Nishiumi, Anna Sou, Hisako Komada, Yuko Okada, Yushi Hirota, Yoshikazu Tamori & Wataru Ogawa. (2018) Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study. Diabetes Therapy 9:5, pages 2067-2079.
Crossref
Crossref
V. K. Bayrasheva, A. Y. Babenko, A. A. Bayramov, S. G. Chefu, I. S. Shatalov, I. Y. Pchelin, A. N. Arefieva & E. N. Grineva. (2017) PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN. Medical Council:3, pages 8-16.
Crossref
Crossref
Michael A. NauckJuris J. MeierMatthew A. CavenderMirna Abd El AzizDaniel J. Drucker. (2017) Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation 136:9, pages 849-870.
Crossref
Crossref